Around 130 AstraZeneca staff will transfer to Sobi as the Swedish company, widely known as Sobi, takes over marketing of the drug Synagis in the United States.
AstraZeneca sells infant drug rights to Sobi for $1.5 bln upfront
More from Industry NewsMore posts in Industry News »
- Four COVID vaccines for children currently in trial phase: Govt tells Rajya Sabha
- Biocon ties up with Tabuk Pharmaceuticals to commercialise speciality medicines in Middle East
- Not enough orders, may cut Covishield output by 50%: SII
- Experts stress on Booster dose to avert third wave due to Omicron cases
- ZyCov-D, 4th vaccine in West Bengal, may be rolled out in mid-December